Share Name Share Symbol Market Type Share ISIN Share Description
Alliance Pharma LSE:APH London Ordinary Share GB0031030819 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.25p +0.47% 53.00p 51.25p 52.75p 52.50p 52.00p 52.00p 85,989 16:35:19
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 97.5 22.2 3.9 13.8 250.67

Alliance Pharma (APH) Latest News

More Alliance Pharma News
Alliance Pharma Takeover Rumours

Alliance Pharma (APH) Share Charts

1 Year Alliance Pharma Chart

1 Year Alliance Pharma Chart

1 Month Alliance Pharma Chart

1 Month Alliance Pharma Chart

Intraday Alliance Pharma Chart

Intraday Alliance Pharma Chart

Alliance Pharma (APH) Discussions and Chat

Alliance Pharma Forums and Chat

Date Time Title Posts
31/7/201708:47Alliance Pharma pays Dividends816
07/11/201615:35Alliance Pharma plc1
15/7/201310:15ALLIANCE PHARMA – 2005 Strong Riser611
16/6/201111:57why the sell off1
13/2/200909:18Suddenly there's Life!14

Add a New Thread

Alliance Pharma (APH) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Alliance Pharma trades in real-time

Alliance Pharma (APH) Top Chat Posts

Alliance Pharma Daily Update: Alliance Pharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker APH. The last closing price for Alliance Pharma was 52.75p.
Alliance Pharma has a 4 week average price of 49.25p and a 12 week average price of 49.25p.
The 1 year high share price is 57.50p while the 1 year low share price is currently 41.50p.
There are currently 472,963,997 shares in issue and the average daily traded volume is 489,770 shares. The market capitalisation of Alliance Pharma is £250,670,918.41.
mazarin: The timing of such news is always going to be difficult, however 9 mins before close (16.21hrs) on last day of the week certainly 'leaves a bad taste'. APH's BoD will need to consider more transparency on the timetable leading up to this announcement to retain credibility. Regulatory Approval for any of their products (or disapproval) is a matter of some significance to share price value. Particularly when not long ago APH was anticipating £250mln 'potential sales of Diclectin across UK/European market with a differentiated product addressing an unmet need.' For details, see:
arf dysg: I notice that the International Misery Fund said that we're screwed, blued and tattooed. Putting it in slightly more formal language, the predictions for growth in the USA and the UK have gone down a little. Perhaps that's why everyone's taking drugs as if there's no tomorrow, so the APH share price has gone up.
pollnagorm: Share price interests me not his finances , not to be rude about it .
pimpernel4: Fair enough and good luck to you ramridge. There seems to have been plenty of appetite at 44p this morning at just a 10% premium to the placement price. The compelling thing about APH is its relatively small free float of shares. As we saw earlier in the year it does not take much to get it motoring and the majority of the new shares must surely now sit in hands that are in it for the mid to long term. Let's see what the end of year share price is.
domple: there must be a big seller as there have been tens and tens of £thousands bought recently and the share price hasn't moved much.
rivaldo: RNS - interims confirmed for 9th September (a day earlier than last year!). Michael, thanks for post 611 above. I suspect your last paragraph is indeed the case as regards the rise in the share price, i.e simply that sellers have completed their disposals and prospects have brightened - plus the possibility of further (and larger) acquisitions.
cisk: Michael, many thanks for the excellent précis. It really chimes with my earlier posts as to what's behind the share price rise - i.e. no specific reason but a combination of favourable factors. I've seen JD present - and had lengthy post-presentation conversations a handful of times and he's always refreshing, affable, to the point and cautiously optimistic. I suspect the share price got ahead of itself a little; and suspect we'll see a decline to late 40s / early 50s with no acquisition news. Regardless, it's a great company with solid prospects and one to tuck away. Thanks again.
michaelmcandrew: Attended this evening's Shares Magazine presentation by John Dawson. His input was about the company in general with no new financial information. His figures were taken from the 2014 annual results so I won't rehash them - they are all in the annual report. He was obviously constrained about revealing new information by the impending interim results in early September. [So, a strange time to do the presentation?] The Q&A were interesting [but not surprising for those of us who have heard JD speak in the past] :- * APH has facilities of £18m approved and available for purchases * any acquisitions will be established products with no marketing risk * before a product is bought in there is a very extensive due diligence process to try and ensure that there has been no cooking of the books by the vendor * there is no R&D spend because APH doesn't do R&D but they do spend extensively on promotion [within limits that do not damage profitability] * It is capitalism when a company is bought because it has a higher break-up value than it's cost. APH would rely on shareholders perception of future prospects to ward off any approach * JD knows of nothing driving the recent rise in the share price. Suggested that the company had treaded water and faced headwinds over the past 3 or 4 years resulting in nervousness amongst investors. He thought that there was now a perception that the headwinds had abated leading to the rise in share price. There had been a number of very large purchases recently.
rivaldo: Hardman have just released their monthly research summary for August. There's a brief summary of APH's trading update - nothing new, but the inbvestment summary is a useful précis: "Investment summary and share performance: The share price has performed very strongly over the past month, rising 36% and underpinned by above-average trading volumes, as the market reflected on the trading statement and future outlook for growth. Trading on FY15 prospective PE of 16.7x with a 2014-2018 EPS CAGR estimate of 10%, EV/EBITDA of 12.1x with a FCF yield of 6.1%. The dividend yield is 1.9% and 3.1x covered. Interim results are due to be released on 9th September."
mazarin: I find it odd to find ADVFN regularly 'mis-quote' APH share Price by as much as 3% at times. Today for example APH opened up 1.25p at 43p, but ADVFN show it as unchanged at 41.8p, both Google and APH's own webpage show it at 43p.
Alliance Pharma share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20170821 02:32:25